Impact of metformin on recurrence and progression in nonmuscle invasive bladder cancer

Abstract

Purpose: To investigate the effect of metformin use on recurrence and progression in nonmuscle invasive bladder cancer patients (NMIBC). Material method: Patients who underwent primary transurethral bladder tumor resection between 2016 and 2020 were screened. Only patients with NMIBC were included in the study. The patients were divided into two groups according to the use of metformin and the groups were compared in terms of recurrence and progression. Results: According to inclusion criteria 176 NIMBC patients were included in the study. Metformin use was detected in 37 patients. The demographic characteristics and follow-up times of the patients were similar between the user and nonuser groups. Recurrence was detected in only 8.1% of the metformin user group. On the other hand, the recurrence rate was 32.4% in the nonuser group. There was no progression in the metformin user group. But in the non-user group progression rate was 8,6%. Conclusion: In our study, we found that recurrence and progression rates were lower in metformin-using patients. Prospective randomized trials are needed to understand the effects of metformin use on bladder cancer.

Keywords

• Urinary Bladder Neoplasms
• Metformin
• Recurrence

Project Number

2022/40-12

Ethical Statement

The protocol for this research project has been approved by a suitably constituted Ethics Committee of the institution and it conforms to the provisions of the Declaration of Helsinki. Committee of Dokuz Eylul University interventional research, Approval No. 2022/40-12. All informed consent was obtained from the subjects.

Thanks

The authors thank all the patients, their families, and caregivers for their participation in this study.

References

1. 1. Babjuk M, Oosterlinck W, Sylvester R, et al. Guidelines on Bladder Cancer (TaT1 and CIS). Eur Urol. 2012;31:1-36.
2. 2. Van Rhijn BWG, Burger M, Lotan Y, et al. Recurrence and Progression of Disease in Non-Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy. Eur Urol. 2009;56(3):430-442. doi:10.1016/j.eururo.2009.06.028
3. 3. Xu Y, Huo R, Chen X, Yu X. Diabetes mellitus and the risk of bladder cancer: A PRISMA-compliant meta-analysis of cohort studies. Med (United States). 2017;96(46). doi:10.1097/MD.0000000000011596
4. 4. Liu Q, Yuan W, Tong D, et al. Metformin represses bladder cancer progression by inhibiting stem cell repopulation via COX2/PGE2/STAT3 axis. Oncotarget.2016;7(19):28235-28246. doi: 10.18632/oncotarget.8595
5. 5. Heidari F, Zade SA, Hosseini SHM, Ghadian A. Metformin for the prevention of bladder cancer recurrence: Is it effective? Nephrourol Mon. 2016;8(3). doi:10.5812/numonthly.30261
6. 6. Ma SJ, Zheng YX, Zhou PC, Xiao YN, Tan HZ. Metformin use improves survival of diabetic liver cancer patients: Systematic review and meta-analysis. Oncotarget.2016;7(40):66202-66211. doi:10.18632/oncotarget.11033
7. 7. EL-Arabey AA. New insight for metformin against bladder cancer. Genes Environ. 2017;39(1):1-8. doi:10.1186/s41021-017-0074-z
8. 8. Dougan S, Gilbart VL, Sinka K, Evans BG. HIV infections acquired through heterosexual intercourse in the United Kingdom: Findings from national surveillance. Br Med J. 2005;330(7503):1303-1304. doi:10.1136/bmj.38393.572188.EB

9. 9. Wu Y, Zheng Q, Li Y, et al. Metformin targets a YAP1-TEAD4 complex via AMPKα to regulate CCNE1/2 in bladder cancer cells. J Exp Clin Cancer Res. 2019;38(1):1-16. doi:10.1186/s13046-019-1346-1
10. 10. Hu J, Chen JB, Cui Y, et al. Association of metformin intake with bladder cancer risk and oncologic outcomes in type 2 diabetes mellitus patients: A systematic review and meta-analysis. Med (United States)2018;97(30). doi:10.1097/MD.0000000000011596
11. 11. Wang Z, Ong WYF, Shen T, et al. Beyond diabetes mellitus: role of metformin in non-muscle-invasive bladder cancer. Singapore Med J. 2022;63(4):209-213. doi:10.11622/smedj.2020121
12. 12. Zhu Z, Wang X, Shen Z, Lu Y, Zhong S, Xu C. Risk of bladder cancer in patients with diabetes mellitus: An updated meta-analysis of 36 observational studies. BMC Cancer. 2013;13(1):1. doi:10.1186/1471-2407-13-310
13. 13. Zhang P, Li H, Tan X, Chen L, Wang S. Association of metformin use with cancer incidence and mortality: A meta-analysis. Cancer Epidemiol. 2013;37(3):207-218. doi:10.1016/j.canep.2012.12.009
14. 14. Nayan M, Bhindi B, Yu JL, et al. The effect of metformin on cancer-specific survival outcomes in diabetic patients undergoing radical cystectomy for urothelial carcinoma of the bladder. Urol Oncol Semin Orig Investig. 2015;33(9):386.e7-386.e13. doi:10.1016/j.urolonc.2015.05.024
15. 15. Akli S, Zhang XQ, Bondaruk J, et al. Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer. Cell Cycle. 2012;11(7):1468-1476. doi:10.4161/cc.19882